Centre Hospitalier Universitaire de Saint Etienne
610
104
117
339
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
122 terminated/withdrawn out of 610 trials
73.5%
-13.0% vs industry average
9%
55 trials in Phase 3/4
1%
2 of 339 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (610)
Study of the Impact on the Evolution of the Disease in the Medium Term of the Implementation of a System of Extended Follow-up by Telephone Interview of Patients With an Eating Disorder Organized by the Nurses of the Eating Disorder Referral Center
Role: lead
Evaluation of the Reproducibility of a Fatigability Test Fitted to Patients With Spinal Muscular Atrophy
Role: lead
Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma
Role: lead
Effect of a Health Pathway for People With Persistent Symptoms Covid-19
Role: lead
Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study).
Role: lead
Production of Nonverbal Acoustic Signals and Resulting Physiological Responses
Role: lead
Single-stage Surgery With Antibiotic-loaded Hydrogel Coated Implants Versus Two Stage Surgery for Secondary Prevention of Complex Chronic Periprosthetic Hip Joint Infection
Role: lead
Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
Role: lead
Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France
Role: lead
Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia
Role: lead
Perception of Nonverbal Acoustic Signals and Resulting Physiological Responses (SINOVE-PER)
Role: lead
Efficiency of an Optimized Care Organization for Fibromyalgia Patients. The FIMOUV 2 Study
Role: lead
Transcutaneous Vagus Nerve Stimulation as a Complementary Therapy to Exercise in Chronic Fatigue
Role: lead
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
Role: lead
Optimized Rehabilitation After Anterior Cruciate Ligament Before Returning to Sport
Role: lead
Effect of Descemet Membrane Polishing in Fuchs Endothelial Corneal Dystrophy
Role: lead
Individualized Dose of Fibrinogen Following Cardiopulmonary Bypass
Role: lead
Objective Assessment of Skin Damage Using ADHELASKIN in Patients With Systemic Sclerosis
Role: lead
Treatment Strategy in Patients With High-risk of Postextubation Distress in ICU Based on a Lung Ultrasound Score Versus Standard Strategy
Role: collaborator
Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise
Role: lead